Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerhard Sattler

Showing results (31-40 of 65) with videos related to

Pageof 7
Sort By:
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|December 8, 2010
Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown linesGerhard Sattler, Michael J Callander, Doris Grablowitz, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|October 7, 2022
Liquid AbobotulinumtoxinA: Pooled Data From Two Double-Blind, Randomized, Placebo-Controlled Phase III Studies of Glabellar Line TreatmentSaid Hilton, Philippe Kestemont, Gerhard Sattler, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|May 29, 2019
Safe, Effective Chin and Jaw Restoration With VYC-25L Hyaluronic Acid Injectable GelPatricia Ogilvie, Gerhard Sattler, Frodo Gaymans, et al.
Journal of Drugs in Dermatology : JDD|May 9, 2022
Calcium Hydroxyapatite Filler With Integral Lidocaine CaHA (+) for Soft Tissue Augmentation: Results from an Open-Label Multicenter Clinical StudyTatjana Pavicic, Gerhard Sattler, Tanja Fischer, et al.
Clinical, Cosmetic and Investigational Dermatology|September 5, 2020
Safety and Performance of Etermis 3 and 4 in Wrinkles/Folds Treatment and Facial Volume Enhancement: A Prospective, Evaluator-Blinded, Open-Label StudyGerhard Sattler, Martina Kerscher, Ernst Magnus Noah, et al.
Journal of Drugs in Dermatology : JDD|February 5, 2013
Recommendations for the best possible use of botulinum neurotoxin type a (Speywood units) for aesthetic applicationsBerthold Rzany, Alina A M Fratila, Tanja C Fischer, et al.
Journal of Cosmetic Dermatology|February 7, 2022
The subjectively perceived injectability as an early indicator for adverse events?Michael G Alfertshofer, Gerhard Sattler, Konstantin Frank, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|February 7, 2017
A Prospective, Open-Label, Observational, Postmarket Study Evaluating VYC-17.5L for the Correction of Moderate to Severe Nasolabial Folds Over 12 MonthsGerhard Sattler, Wolfgang G Philipp-Dormston, Helga Van Den Elzen, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|October 17, 2020
IncobotulinumtoxinA Is an Effective and Well-Tolerated Treatment for Upper Facial Lines: Results From an Open-Label Extension Period of a Phase III StudyPatrick Trevidic, Simon A Connolly, Bernard Biwer, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|August 11, 2018
Phase 3 Study of OnabotulinumtoxinA Distributed Between Frontalis, Glabellar Complex, and Lateral Canthal Areas for Treatment of Upper Facial LinesKoenraad De Boulle, William Philip Werschler, Michael H Gold, et al.
Pageof 7

Showing results (31-40 of 65) with videos related to

Sort By:
Pageof 7
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|December 8, 2010
Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown linesGerhard Sattler, Michael J Callander, Doris Grablowitz, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|October 7, 2022
Liquid AbobotulinumtoxinA: Pooled Data From Two Double-Blind, Randomized, Placebo-Controlled Phase III Studies of Glabellar Line TreatmentSaid Hilton, Philippe Kestemont, Gerhard Sattler, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|May 29, 2019
Safe, Effective Chin and Jaw Restoration With VYC-25L Hyaluronic Acid Injectable GelPatricia Ogilvie, Gerhard Sattler, Frodo Gaymans, et al.
Journal of Drugs in Dermatology : JDD|May 9, 2022
Calcium Hydroxyapatite Filler With Integral Lidocaine CaHA (+) for Soft Tissue Augmentation: Results from an Open-Label Multicenter Clinical StudyTatjana Pavicic, Gerhard Sattler, Tanja Fischer, et al.
Clinical, Cosmetic and Investigational Dermatology|September 5, 2020
Safety and Performance of Etermis 3 and 4 in Wrinkles/Folds Treatment and Facial Volume Enhancement: A Prospective, Evaluator-Blinded, Open-Label StudyGerhard Sattler, Martina Kerscher, Ernst Magnus Noah, et al.
Journal of Drugs in Dermatology : JDD|February 5, 2013
Recommendations for the best possible use of botulinum neurotoxin type a (Speywood units) for aesthetic applicationsBerthold Rzany, Alina A M Fratila, Tanja C Fischer, et al.
Journal of Cosmetic Dermatology|February 7, 2022
The subjectively perceived injectability as an early indicator for adverse events?Michael G Alfertshofer, Gerhard Sattler, Konstantin Frank, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|February 7, 2017
A Prospective, Open-Label, Observational, Postmarket Study Evaluating VYC-17.5L for the Correction of Moderate to Severe Nasolabial Folds Over 12 MonthsGerhard Sattler, Wolfgang G Philipp-Dormston, Helga Van Den Elzen, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|October 17, 2020
IncobotulinumtoxinA Is an Effective and Well-Tolerated Treatment for Upper Facial Lines: Results From an Open-Label Extension Period of a Phase III StudyPatrick Trevidic, Simon A Connolly, Bernard Biwer, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|August 11, 2018
Phase 3 Study of OnabotulinumtoxinA Distributed Between Frontalis, Glabellar Complex, and Lateral Canthal Areas for Treatment of Upper Facial LinesKoenraad De Boulle, William Philip Werschler, Michael H Gold, et al.
Pageof 7